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Tocilizumab is a monoclonal humanized anti-IL-6-receptor antibody used for the treatment of rheumatoid arthritis. The safety
of tocilizumab in HCV patients is an open question. We report on safety and eﬃcacy of tocilizumab in a 71-year-old female with
rheumatoid arthritis and chronic hepatitis C. Monotherapy with tocilizumab (8mg/kg every 4 weeks, i.v.) was prescribed after the
discontinuation, determined by clinical ineﬃcacy, of anti-TNF-alfa agents (adalimumab and, subsequently, etanercept). We have
registered an optimal and rapid clinical response to tocilizumab with early remission (SDAI <3.3 since 4 weeks). The safety was
good with no adverse events and maintenance, during a six-month followup, of normal liver enzymes. These data suggest a good
safety proﬁle of tocilizumab in patients with rheumatoid arthritis and chronic hepatitis C virus pathology.
1.Introduction
Tocilizumab (TCZ) is a monoclonal humanized anti-
Interleukin-6-(IL-6-) receptor antibody, which has been
showntobehighlyandrapidlyeﬃcaciousfortheclinicaland
radiographic outcome of patients with severe rheumatoid
arthritis (RA) [1]. TCZ is eﬃcacious also as a monotherapy,
is capable to induce a rapid remission of arthritis activity,
and ameliorates the systemic manifestations of rheumatoid
arthritis. The safety proﬁle of tocilizumab in clinical trials
was good with adverse events rate similar to control groups.
In “real life,” the safety proﬁle of tocilizumab in RA patients
with chronic hepatitis C is an open question. Actually (on
02 December 2011) there is only one article in PubMed,
ac a s er e p o r t[ 2]. Some studies have evidenced a potential
pathogenetic role of IL-6 for the liver and systemic man-
ifestations of HCV infection [3, 4]. This evidence permits
to hypothesize an interference of tocilizumab on the course
of HCV pathology. In this paper we have described the
eﬃcacy and safety proﬁle of tocilizumab during a 24-
week followup of an HCV patient with severe rheuma-
toid arthritis, nonresponder to methotrexate and TNF-alfa
agents.
2.CaseReport
A 71-year-old Caucasian female patient presented to our
division on 18 April 2011. She had been diagnosed with
chronic hepatitis C (at 51 year of age) and rheumatoid
arthritis (at 58 year of age). Hepatitis C virus genotype was
2 a / 2 c .Al i v e rb i o p s y ,a t5 7y e a ro fa g e ,d o c u m e n t e dac h r o n i c
active hepatitis of moderate severity with inﬂammatory
intralobular and portal inﬁltrates, and moderate piece-meal
necrosis. The clinical course of chronic HCV pathology was
benign with constant normality of alanine/aspartate amino-
transferase (ALT/AST), and absence of liver or systemic
impairment. Ultrasonography documented an augment of
liver volume, a homogeneous echostructure, and the absence
of focal lesions or cirrhosis. Rheumatoid arthritis was severe
since onset and was immediately treated with methotrexate
(15–20mg every 7 days). At 67 year of age, the patient began
an anti-TNF-alfa treatment with adalimumab (40mg s.c.
every14days)incombinationwithmethotrexate(20mgi.m.
every 7 days) with rapid and sustained response (remission)
up to 70 years of age when there was a strong relapse of
RA. Methotrexate was interrupted for individual gastroin-
testinal intolerance. At October 2010, the patient started2 Case Reports in Medicine
Table 1: Liver function, etoricoxib requirement, and arthritis activity at baseline and during treatment with tocilizumab in a 71-year-old
female patient with rheumatoid arthritis and HCV Infection.
Parameter Week 0 Week 2 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24
AST (U/L, normal values <31) 18 28 17 21 16 17 18 20
ALT (U/L, normal values <31) 16 31 19 20 14 13 16 18
GGT (U/L, normal values <32) 20 21 11 12 9 10 7 7
ALP (U/L, normal values <360) 136 155 121 120 133 124 122 139
Total bilirubine (mg/dl, normal values <1.1) 0,61 0,70 0,78 0,70 0,91 0,66 0,56 0,80
Direct bilirubine (mg/dl, normal values <0.5) 0,15 0,18 0,20 0,19 0,23 0,19 0,14 0,21
Etoricoxib 90 mg tablet requirement (numbers/week) 5 1 0 0 0 0 0 0
SDAI (remission <3,3) 59,24 4 1 1 0,5 0,1 0,2 0,2
monotherapy with etanercept (50mg s.c. every 7 days)
without a signiﬁcant improvement of disease activity (after
six months, SDAI ( simpliﬁed disease activity score ) >40).
At the ﬁrst visit at our division (on 18 April 2011), she has
shown the persistence of an elevated activity of rheumatoid
arthritis (SDAI = 50,5) with numerous tender and swollen
joints, prolonged (some hours) morning stiﬀness and strong
disability. The analysis of liver exams showed normal values
of all parameters. The result of quantitative HCV-RNA was
6962286IU/mL. The levels of alfa-fetoprotein were nor-
mal (2,9ng/mL, normal values <7). Anticyclic citrullinated
peptide antibodies (anti-CCP) were positive. Rheumatoid
factor was negative. We have prescribed the interruption, for
ineﬃcacy, of treatment with etanercept. On 3 June 2011, the
patient began monotherapy with tocilizumab (8mg/kg i.v.
every four weeks). At this date (week 0) and during followup
(weeks 2, 4, 8, 12, 16, 20, 24), we have determined and
collected the subsequent parameters:
(i) liver exams: alanine aminotransferase (ALT, U/L,
normal <31), aspartate aminotransferase (AST, U/L,
normal<31),gamma-glutamyltranspeptidase(GGT,
U/L, normal <32), alkaline phosphatase (ALP, U/L,
normal <360), total bilirubin (mg/dL, normal <1,1),
direct bilirubin (mg/dL, normal <0,5);
(ii) etoricoxib (90mg) requirement (number of tablets/
week);
(iii) SDAI (Simpliﬁed Disease Activity Index): it is a
validated index of activity of rheumatoid arthritis.
SDAI is the numerical sum of 5 parameters: tender
joint count (0–28), swollen joint count (0–28),
patient global assessment of disease activity (0–10),
physicianglobalassessmentofdiseaseactivity(0–10),
a n dl e v e lo fC - r e a c t i v ep r o t e i n( m g / d L ) .A nS D A I
value of >40 indicates high activity of disease, an
SDAIvalueof20–40indicatesamoderateRAactivity,
an SDAI value <20 indicates a mild disease, an SDAI
value <3.3 indicates the remission of rheumatoid
arthritis.
The monotherapy with tocilizumab, in this patient, has
determined a rapid clinical improvement: after 2 weeks, we
have veriﬁed a signiﬁcant reduction of SDAI, from 59,24 to
4. The remission of rheumatoid arthritis (SDAI <3,3) was
already registered after 4 weeks of treatment and persisted
during all the followup (at present 24 weeks).
The analysis of liver exams has shown the maintenance
of normal liver function during all the followup. No
signs of cirrhosis were detected. No other adverse events
associated to tocilizumab treatment were registered during
the observation period. The etoricoxib requirement, high at
baseline (5 tablets/week), was reduced to 1 tablet/week after
2 weeks and to 0 tablet/week after 4 weeks. The results of
this study were collected in Table 1. The course of AST, ALT,
and GGT was shown in Figure 1. The evaluation of activity
of rheumatoid arthritis with SDAI during the treatment with
tocilizumab was illustrated in Figure 2.
3. Discussion
Biologic therapy (anti-TNF-alfa agents, abatacept, ritux-
imab, tocilizumab) has dramatically improved the clinical
and anatomic course of rheumatoid arthritis. The use of
these agents in patient with early arthritis can determine
a rapid clinical remission and an arrest or, at least, a
substantial slowing of radiological progression. Tocilizumab,
particularly, has shown a high and rapid eﬃcacy and is the
sole biologic agent that has been superior to methotrexate
as monotherapy for the clinical improvement of rheuma-
toid arthritis. The safety proﬁle of tocilizumab showed by
clinical trials is good. The most common adverse events
associated to tocilizumab treatment were infections, gas-
trointestinal symptoms, alteration of liver enzymes, hyper-
cholesterolemia, neutropenia, and infusion reactions. The
rate of adverse events was similar between tocilizumab
and control groups. Most adverse events associated to
tocilizumab were mild or moderate. The tolerability and
safety of tocilizumab in RA patients with HCV infection
in clinical practice is a relevant open question. An analysis
of medical literature with PubMed (keywords: tocilizumab
and Hepatitis C Virus), executed on 02 December 2011, has
documented the presence of only one study, a case report by
Nagashima and coworkers. Serum IL-6 and its soluble recep-
tor levels were correlated with liver function impairment
and liver ﬁbrosis. In HCV patients with chronic hepatitis,
cirrhosis, hepatocellular carcinoma, or HCV-related mixed
cryoglobulinemia, augmented serum levels of IL-6 were
detected[5,6].Thepotential pathogenetic contributeofIL-6



































































































































SDAI >40: high activity
SDAI: 20–40: moderate activity
SDAI <20: mild activity
SDAI <3.3 = remission
Figure 2: Rheumatoid arthritis activity (SDAI) during treatment
with tocilizumab.
HCVinfectionsuggestsapossibleinterferenceoftocilizumab
on outcome of chronic Hepatitis C. Our paper has shown
the absence of liver impairment of tocilizumab with mainte-
nance of normal AST, ALT, GGT, ALP, and bilirubine levels
during all the followup. These results suggest, as well as for
anti-TNF-alfaagents,agoodliversafetyoftocilizumabinRA
patients with HCV infection. These suggestions obviously
have to be conﬁrmed by controlled and randomized trials
and/or large observational studies. The rapid remission of
arthritis determined in our patient by tocilizumab is in
complete accordance with the trial results and is a crucial
objective of biologic therapy, particularly in patients with
early arthritis, because recent studies show that the rapidity
of remission is strictly associated to a better radiologic
outcome of rheumatoid arthritis. The rapid interruption,
since 4 weeks, of etoricoxib intake was another positive eﬀect
of tocilizumab on the course of rheumatoid arthritis and
HCV disease in this patient.
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